↑BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 152. ISBN978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑"ARBs", Angiotensin II Receptor Antagonists, Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012, PMID31643954, retrieved 2020-03-21, The angiotensin II receptor antagonists, also known as angiotensin receptor blockers (ARBs), are a family of agents that bind to and inhibit the angiotensin II type 1 receptor (AT1) and thus inhibit the renin-angiotensin system and its cascade of effects in causing arteriolar contraction and sodium retention. While angiotensin converting enzyme (ACE) inhibitors block the cleavage of angiotensin I to angiotensin II, the active peptide that causes a pressor response, the ARBs inhibit its peripheral action.
↑Massachusetts, Christina C. Andros, PharmD/MBA Candidate 2017 Western New England University College of Pharmacy Springfield, Massachusetts Jared L. Ostroff, PharmD, BCACP Clinical Assistant Professor of Ambulatory Care Western New England University College of Pharmacy Department of Pharmacy Practice Springfield, Massachusetts Marissa L. Wolff, PharmD, BCPS Clinical Assistant Professor of Ambulatory Care Western New England University College of Pharmacy Department of Pharmacy Practice Springfield. "An Overview of Generic Angiotensin Receptor Blockers". www.uspharmacist.com (in ଇଂରାଜୀ). Retrieved 19 April 2021.{{cite web}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
